Overview

• The agreement applies a 15% levy to most finished drugs and active ingredients imported from European Union member states.
• European Commission President Ursula von der Leyen confirmed exemptions for some generics, though U.S. fact sheets omit such carve-outs.
• ING analysts estimate the tariff will add about $13 billion annually to import costs once existing stockpiles are depleted.
• Blockbuster brand-name medications made in Europe, including Ozempic, Wegovy and Keytruda, are expected to see list-price hikes passed on to payers and patients.
• Pharmaceutical companies are exploring U.S. manufacturing expansions and potential cuts to research and development budgets to offset added tariff burdens.